2022. CLINICAL OBSERVATION OF THE USE OF ORAL VINORELBINE IN THE TREATMENT OF DISSEMINATED ESTROGEN-RECEPTORPOSITIVE, HER2-NEGATIVE BREAST CANCER. World Bulletin of Social Sciences. 7, (Feb. 2022), 1–4.